ALRN-6924 blocks wild-type p53 cells, including normal bone marrow cells, in the S phase, thereby potentially preventing chemotherapy-induced toxicity while preserving or enhancing efficacy against p53-mutant cancers. The gene discussed is TP53; the disease is cancer.